“Sick-but-not-dead”: multiple paths to catecholamine deficiency in Lewy body diseases

References

• Amino, T., Orimo, S., Itoh, Y., Takahashi, A., Uchihara, T., & Mizusawa, H. (2005). Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathology (Zurich, Switzerland), 15(1), 29–34. https://doi.org/10.1111/j.1750-3639.2005.tb00097.x
   PubMed Web of Science ®Google Scholar
• Chiu, C. C., Yeh, T. H., Lai, S. C., Wu-Chou, Y. H., Chen, C. H., Mochly-Rosen, D., Huang, Y. C., Chen, Y. J., Chen, C. L., Chang, Y. M., Wang, H. L., & Lu, C. S. (2015). Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism. Experimental Neurology, 263, 244–253. https://doi.org/10.1016/j.expneurol.2014.09.016
   PubMed Web of Science ®Google Scholar
• DelleDonne, A., Klos, K. J., Fujishiro, H., Ahmed, Z., Parisi, J. E., Josephs, K. A., Frigerio, R., Burnett, M., Wszolek, Z. K., Uitti, R. J., Ahlskog, J. E., & Dickson, D. W. (2008). Incidental Lewy body disease and preclinical Parkinson disease. Archives of Neurology, 65(8), 1074–1080. https://doi.org/10.1001/archneur.65.8.1074
   PubMedGoogle Scholar
• Djamshidian, A., & Lees, A. J. (2014). Can stress trigger Parkinson's disease? Journal of Neurology, Neurosurgery, and Psychiatry, 85(8), 878–881. https://doi.org/10.1136/jnnp-2013-305911
   PubMed Web of Science ®Google Scholar
• Eisenhofer, G., Kopin, I. J., & Goldstein, D. S. (2004). Catecholamine metabolism: A contemporary view with implications for physiology and medicine. Pharmacological Reviews, 56(3), 331–349. https://doi.org/10.1124/pr.56.3.1
   PubMed Web of Science ®Google Scholar
• Fluharty, S. J., Rabow, L. E., Stricker, E. M., & Zigmond, M. J. (1985). Tyrosine hydroxylase activity in the sympathoadrenal system under basal and stressful conditions: Effect of 6-hydroxydopamine. The Journal of Pharmacology and Experimental Therapeutics, 235(2), 354–360.
   PubMed Web of Science ®Google Scholar
• Goldstein, D. S., Holmes, C., Kopin, I. J., & Sharabi, Y. (2011). Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. The Journal of Clinical Investigation, 121(8), 3320–3330. https://doi.org/10.1172/JCI45803
   PubMed Web of Science ®Google Scholar
• Goldstein, D. S., Holmes, C., Sullivan, P., Mash, D. C., Sidransky, E., Stefani, A., Kopin, I. J., & Sharabi, Y. (2015). Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration. Parkinsonism & Related Disorders, 21(9), 1013–1022. https://doi.org/10.1016/j.parkreldis.2015.07.009
   PubMed Web of Science ®Google Scholar
• Goldstein, D. S., & Orimo, S. (2009). Cardiac sympathetic neuroimaging: Summary of the First International Symposium. Clinical Autonomic Research, 19(3), 137–136. https://doi.org/10.1007/s10286-009-0002-9
   PubMed Web of Science ®Google Scholar
• Goldstein, D. S., Pekker, M. J., Eisenhofer, G., & Sharabi, Y. (2019). Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases. JCI Insight, 4(16):e130441. https://doi.org/10.1172/jci.insight.130441
   Web of Science ®Google Scholar
• Goldstein, D. S., & Sharabi, Y. (2019). The heart of PD: Lewy body diseases as neurocardiologic disorders. Brain Research, 1702, 74–84. https://doi.org/10.1016/j.brainres.2017.09.033
   PubMed Web of Science ®Google Scholar
• Goldstein, D. S., Sullivan, P., Cooney, A., Jinsmaa, Y., Sullivan, R., Gross, D. J., Holmes, C., Kopin, I. J., & Sharabi, Y. (2012). Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: Relevance to the pathogenesis of Parkinson's disease. Journal of Neurochemistry, 123(6), 932–943. https://doi.org/10.1111/j.1471-4159.2012.07924.x
   PubMed Web of Science ®Google Scholar
• Goldstein, D. S., Sullivan, P., Holmes, C., Kopin, I. J., Basile, M. J., & Mash, D. C. (2011). Catechols in post-mortem brain of patients with Parkinson disease. European Journal of Neurology, 18(5), 703–710. https://doi.org/10.1111/j.1468-1331.2010.03246.x
   PubMed Web of Science ®Google Scholar
• Goldstein, D. S., Sullivan, P., Holmes, C., Kopin, I. J., Sharabi, Y., & Mash, D. C. (2015). Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy. Parkinsonism & Related Disorders, 21(6), 567–572. https://doi.org/10.1016/j.parkreldis.2015.03.006
   PubMed Web of Science ®Google Scholar
• Goldstein, D. S., Sullivan, P., Holmes, C., Mash, D. C., Kopin, I. J., & Sharabi, Y. (2017). Determinants of denervation-independent depletion of putamen dopamine in Parkinson’s disease and multiple system atrophy. Parkinsonism & Related Disorders, 35, 88–91. https://doi.org/10.1016/j.parkreldis.2016.12.011
   PubMed Web of Science ®Google Scholar
• Goldstein, D. S., Sullivan, P., Holmes, C., Miller, G. W., Alter, S., Strong, R., Mash, D. C., Kopin, I. J., & Sharabi, Y. (2013). Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. Journal of Neurochemistry, 126(5), 591–603. https://doi.org/10.1111/jnc.12345
   PubMed Web of Science ®Google Scholar
• Goldstein, D. S., Sullivan, P., Holmes, C., Miller, G. W., Sharabi, Y., & Kopin, I. J. (2014). A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson disease. Journal of Neurochemistry, 131(2), 219–228. https://doi.org/10.1111/jnc.12766
   PubMed Web of Science ®Google Scholar
• Guo, L., Esler, M. D., Sari, C., Phillips, S., Lambert, E. A., Straznicky, N. E., Lambert, G. W., & Corcoran, S. J. (2018). Does sympathetic dysfunction occur before denervation in pure autonomic failure? Clinical Science, 132(1), 1–16. https://doi.org/10.1042/CS20170240
   PubMed Web of Science ®Google Scholar
• Jain, S., & Goldstein, D. S. (2012). Cardiovascular dysautonomia in Parkinson disease: From pathophysiology to pathogenesis. Neurobiology of Disease, 46(3), 572–580. https://doi.org/10.1016/j.nbd.2011.10.025
   PubMed Web of Science ®Google Scholar
• Jinsmaa, Y., Sharabi, Y., Sullivan, P., Isonaka, R., & Goldstein, D. S. (2018). 3,4-Dihydroxyphenylacetaldehyde-induced protein modifications and their mitigation by N-acetylcysteine. The Journal of Pharmacology and Experimental Therapeutics, 366(1), 113–124. https://doi.org/10.1124/jpet.118.248492
   PubMed Web of Science ®Google Scholar
• Kang, S. S., Liu, X., Ahn, E. H., Xiang, J., Manfredsson, F. P., Yang, X., Luo, H. R., Liles, L. C., Weinshenker, D., & Ye, K. (2020). Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus. The Journal of Clinical Investigation, 130(1), 422–437. https://doi.org/10.1172/JCI130513
   PubMed Web of Science ®Google Scholar
• Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988). Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. The New England Journal of Medicine, 318(14), 876–880. https://doi.org/10.1056/NEJM198804073181402
   PubMed Web of Science ®Google Scholar
• Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013). Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain, 136(Pt 8), 2419–2431. https://doi.org/10.1093/brain/awt192
   PubMed Web of Science ®Google Scholar
• Kubovcakova, L., Krizanova, O., & Kvetnansky, R. (2004). Identification of the aromatic l-amino acid decarboxylase gene expression in various mice tissues and its modulation by immobilization stress in stellate ganglia. Neuroscience, 126(2), 375–380. https://doi.org/10.1016/j.neuroscience.2004.04.005
   PubMed Web of Science ®Google Scholar
• Kvetnansky, R., Weise, V. K., & Kopin, I. J. (1970). Elevation of adrenal tyrosine hydroxylase and phenylethanolamine-N-methyl transferase by repeated immobilization of rats. Endocrinology, 87(4), 744–749. https://doi.org/10.1210/endo-87-4-744
   PubMed Web of Science ®Google Scholar
• Lamotte, G., Holmes, C., Wu, T., & Goldstein, D. S. (2019). Long-term trends in myocardial sympathetic innervation and function in synucleinopathies. Parkinsonism & Related Disorders, 67, 27–33. https://doi.org/10.1016/j.parkreldis.2019.09.014
   PubMed Web of Science ®Google Scholar
• Lohr, K. M., Bernstein, A. I., Stout, K. A., Dunn, A. R., Lazo, C. R., Alter, S. P., Wang, M., Li, Y., Fan, X., Hess, E. J., Yi, H., Vecchio, L. M., Goldstein, D. S., Guillot, T. S., Salahpour, A., & Miller, G. W. (2014). Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America, 111(27), 9977–9982. https://doi.org/10.1073/pnas.1402134111
   PubMed Web of Science ®Google Scholar
• Mexas, L. M., Florang, V. R., & Doorn, J. A. (2011). Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite. Neurotoxicology, 32(4), 471–477. https://doi.org/10.1016/j.neuro.2011.03.013
   PubMed Web of Science ®Google Scholar
• Nankova, B., Kvetnansky, R., McMahon, A., Viskupic, E., Hiremagalur, B., Frankle, G., Fukuhara, K., Kopin, I. J., & Sabban, E. L. (1994). Induction of tyrosine hydroxylase gene expression by a nonneuronal nonpituitary-mediated mechanism in immobilization stress. Proceedings of the National Academy of Sciences of the United States of America, 91(13), 5937–5941. https://doi.org/10.1073/pnas.91.13.5937
   PubMed Web of Science ®Google Scholar
• Orimo, S., Amino, T., Takahashi, A., Kojo, T., Uchihara, T., Mori, F., Wakabayashi, K., & Takahashi, H. (2006). Cardiac sympathetic denervation in Lewy body disease. Parkinsonism & Related Disorders, 12(Suppl. 2), S99–S105. https://doi.org/10.1016/j.parkreldis.2006.05.030
   Google Scholar
• Pifl, C., Rajput, A., Reither, H., Blesa, J., Cavada, C., Obeso, J. A., Rajput, A. H., & Hornykiewicz, O. (2014). Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. The Journal of Neuroscience, 34(24), 8210–8218. https://doi.org/10.1523/JNEUROSCI.5456-13.2014
   PubMed Web of Science ®Google Scholar
• Plotegher, N., Berti, G., Ferrari, E., Tessari, I., Zanetti, M., Lunelli, L., Greggio, E., Bisaglia, M., Veronesi, M., Girotto, S., Dalla Serra, M., Perego, C., Casella, L., & Bubacco, L. (2017). DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Scientific Reports, 7, 40699. https://doi.org/10.1038/srep40699
   PubMed Web of Science ®Google Scholar
• Sugama, S., Sekiyama, K., Kodama, T., Takamatsu, Y., Takenouchi, T., Hashimoto, M., Bruno, C., & Kakinuma, K. (2016). Chronic restraint stress triggers dopaminergic and noradrenergic neurodegeneration: Possible role of chronic stress in the onset of Parkinson's disease. Brain, Behavior, and Immunity, 51, 39–46. https://doi.org/10.1016/j.bbi.2015.08.015
   PubMed Web of Science ®Google Scholar
• Youdim, M. B., & Weinstock, M. (2004). Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology, 25(1–2), 243–250. https://doi.org/10.1016/S0161-813X(03)00103-7
   PubMed Web of Science ®Google Scholar